Skip to main content

Progress Update on MedMira’s COVID-19 Product Family

Written by Customer Service on . Posted in Public Companies.

HALIFAX, Nova Scotia, Jan. 29, 2021 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. These antibodies bind to the specific parts of the virus, decreasing the viral infectivity and potentially protecting the patient from the severe COVID-19 symptom presentation or future SARS-CoV-2 reinfection. Not all antibodies can block the virus from infecting the patient, and, according to the recent reports, the levels of neutralizing antibodies vary, so as the potency of the antibody protection. Once extensively validated, MedMira’s neutralizing antibody test can effectively pinpoint the antibodies with the blocking capability, thus, potentially, serving as a powerful tool for the qualitative assessment of the antibody status pre- and post-vaccination, as well as providing insights into one’s immunity to SARS-CoV-2. At this time, there is no guarantee that this product will meet all regulatory requirements and receive a subsequent regulatory approval.
“Over the past twenty years, our Research and Development group has played a crucial role in the development of the innovative diagnostic solutions, which allowed us to quickly adapt our RVF® platform and develop this neutralizing antibody test prototype that will greatly complement the current serology assays, including our current REVEALCOVID-19™ PLUS Total Antibody Test,” said Hermes Chan, CEO of MedMira. “For instance, a positive antibody result indicates that you have antibodies in general, while a positive neutralizing antibody test may tell you how effective these antibodies are. This is yet another milestone in the expansion of our COVID-19 product family, and we are excited about what is coming up next.”MedMira is committed to offering an array of high-quality COVID-19 products to address various global market needs and reflect upon the scientific breakthroughs. Regulatory update as well as the latest product development strategy will be publicly announced soon.About MedMiraMedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the Reveal®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow® Technology, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.MedMira Contact
Markus Meile
Chief Financial Officer
MedMira Inc.
ir@medmira.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.